menu search

ATRS / Antares Pharma's Oral Testosterone Treatment Scores FDA Approval

Antares Pharma's Oral Testosterone Treatment Scores FDA Approval
Antares Pharma Inc (NASDAQ: ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for deficiency or absence of. Read More
Posted: Mar 29 2022, 11:46
Author Name: Benzinga
Views: 111661

ATRS News  

Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?

By Zacks Investment Research
April 14, 2022

Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?

Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate re more_horizontal

Why Antares Pharma Stock Is Soaring Today

By Benzinga
April 13, 2022

Why Antares Pharma Stock Is Soaring Today

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (N more_horizontal

Antares Pharma's Oral Testosterone Treatment Scores FDA Approval

By Benzinga
March 29, 2022

Antares Pharma's Oral Testosterone Treatment Scores FDA Approval

Antares Pharma Inc (NASDAQ: ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approv more_horizontal

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 3, 2022

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript more_horizontal

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 3, 2022

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript more_horizontal

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 3, 2022

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript more_horizontal

Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates

By Zacks Investment Research
March 3, 2022

Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates

Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers ho more_horizontal

Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates

By Zacks Investment Research
March 3, 2022

Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates

Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers ho more_horizontal


Search within

Pages Search Results: